Business Wire
29 May 2026, 01:18 UTC · 18h ago
Source · https://www.businesswire.com/news/home/20260528610886/en/IMFINZI%C2%AE-durvalumab-approved-in-the-US-in-first-and-only-immunotherapy-combination-for-patients-with-BCG-na%C3%AFve-high-risk-non-muscle-invasive-bladder-cancer/
Read source
Search tags
Story key points
2 claims · impact-rated
The FDA has approved AstraZeneca's Imfinzi in combination with BCG therapy for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). — FDA approval expands the addressable market for Imfinzi and creates a new revenue stream in the bladder cancer segment.
+0.60The approval is supported by positive results from the POTOMAC Phase III trial. — Clinical trial success validates the drug's efficacy, reducing regulatory risk and supporting commercial adoption.
+0.20Ticker attribution
Model heads
The FDA approved AstraZeneca's drug IMFINZI for the treatment of high-risk non-muscle-invasive bladder cancer.
Continue reading
6 related stories
No ticker relationship head found.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Newsfile Corp
4h ago
